Brown Advisory’s Cytokinetics CYTK Stock Holding History

Brown Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.5M	Sell	614,655 -116,499	-16%	-$7.4M	0.07%	218
2025 Q4	$46.5M	Sell	731,154 -181,032	-20%	-$11.3M	0.06%	212
2025 Q3	$50.1M	Sell	912,186 -83,113	-8%	-$3.42M	0.07%	199
2025 Q2	$32.9M	Sell	995,299 -91,001	-8%	-$3.17M	0.04%	250
2025 Q1	$43.7M	Buy	1,086,300 +9,869	+0.9%	+$454K	0.06%	204
2024 Q4	$50.6M	Sell	1,076,431 -89,560	-8%	-$4.65M	0.06%	205
2024 Q3	$61.6M	Buy	1,165,991 +403,442	+53%	+$22.5M	0.08%	184
2024 Q2	$41.3M	Buy	762,549 +3,015	+0.4%	+$182K	0.05%	235
2024 Q1	$53.3M	Buy	+759,534	New	+$58.7M	0.07%	200
2022 Q1	–	Sell	-11,759	Closed	-$536K	–	1148
2021 Q4	$536K	Buy	+11,759	New	+$454K	﹤0.01%	855

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brown Advisory's CYTK Position: Q1 2026 in Review

Brown Advisory reduced its Cytokinetics (CYTK) stake by 16% in Q1 2026, selling an estimated $7.4M and leaving 614,655 shares worth $40.5M. The position accounts for 0.07% of the portfolio, ranked #218.

Brown Advisory first reported a position in CYTK in Q4 2021 and has held it in 10 quarters since. The position peaked at $61.6M in Q3 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Brown Advisory held 614,655 shares of Cytokinetics worth $40.5M as of Q1 2026.
Brown Advisory sold 116,499 Cytokinetics shares in Q1 2026, an estimated $7.4M.
Cytokinetics made up 0.07% of Brown Advisory's portfolio in Q1 2026, its #218 holding.
Brown Advisory first reported a position in Cytokinetics in Q4 2021 and has held it in 10 quarters since.
Brown Advisory's Cytokinetics position peaked at $61.6M in Q3 2024.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.